XBI241115C101000
- 0.03
- -0.07-70.00%
SPDR S&P Biotech ETF Newsroom
Druckenmiller made significant adjustments in the third quarter: opened positions in Bank of America and Broadcom, continued to increase holdings in the top position Natera.
Natera's position significantly increased by 80.61% compared to the previous quarter. Druckenmiller also established new positions in Broadcom, banks, and pharmaceutical stocks, while completely liquidating News Corp and telecom company Liberty Global, and reducing shareholding in microsoft.
What kind of company is Natera, the largest hold positions of Drew Miller?
Currently, there is a lack of precision in adjuvant therapy plans after tumor (MRD) surgery, while MRD testing can detect molecular abnormalities originating from the tumor, enabling early detection of cancer recurrence and guiding precise postoperative treatment. Huayuan Securities believes that natera's MRD testing business has significant competitive advantages, and its launched Signatera product is expected to become the core driving force behind the company's rapid performance improvement.
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
SPDR S&P Biotech ETF Options Spot-On: On November 14th, 160.61K Contracts Were Traded, With 954.71K Open Interest
On November 14th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 160.61K options for the day, of which put options accounted for 65.41% of the total
Druckenmiller's Duquesne Closes Some Media Holdings, Loads Into Regional Banks, Among Q3 Trades
Cracking The Code: Understanding Analyst Reviews For Incyte
Gilead, Vertex Initiated as New Big Biotech Buys at Citi
Incyte Analyst Ratings
Amgen's Options Frenzy: What You Need to Know
InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia
Gilead Sciences Analyst Ratings
Vertex Pharmaceuticals Analyst Ratings
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Natera Analysts Increase Their Forecasts Following Upbeat Results
10 Health Care Stocks With Whale Alerts In Today's Session
Live On CNBC, Joe Terranova Announces Sold Amgen
Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday
4 Stocks to Watch on Wednesday: AMGN, CSCO and More
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday
Market-Moving News for November 13th